Table 2. Individual drug resistance in relation to the profile of fluoroquinolone and SLI resistance among patients with multidrug-resistant tuberculosis who could have been candidates for a short (9-month) treatment regimen or a bedaquiline-containing regimen*.
| Drug, DST result | Total, N = 1,254 | Candidate patients, no. (%) |
||||
|---|---|---|---|---|---|---|
| Short regimen, FQ-S and SLI-S, n = 952 | BDQ-containing regimen |
|||||
| FQ-R or SLI-R,† n = 302 | FQ-R only, n = 73 | SLI-R only, n = 155 | XDR, n = 74 | |||
| INH, high-dose | ||||||
| NA | 11 (0.9) | 11 (1.2) | 0 | 0 | 0 | 0 |
| R | 1,152 (91.9) | 859 (90.2) | 293 (97.0) | 69 (94.5) | 154 (99.4) | 70 (94.6) |
| S |
91 (7.3) |
82 (8.6) |
9 (3.0) |
4 (5.5) |
1 (0.6) |
4 (5.4) |
| EMB | ||||||
| R | 771 (61.5) | 553 (58.1) | 218 (72.2) | 51 (69.9) | 113 (72.9) | 54 (73) |
| S |
483 (38.5) |
399 (41.9) |
84 (27.8) |
22 (30.1) |
42 (27.1) |
20 (27) |
| FQ | ||||||
| R | 147 (11.7) | 0 | 147 (48.7) | 73 (100) | 0 | 74 (100) |
| S |
1,107 (88.3) |
952 (100) |
155 (51.3) |
0 |
155 (100) |
0 |
| KAN/AMK | ||||||
| R | 219 (17.5) | 0 | 219 (72.5) | 0 | 150 (96.8) | 69 (93.2) |
| S |
1,035 (82.5) |
952 (100) |
83 (27.5) |
73 (100) |
5 (3.2) |
5 (6.8) |
| CAP | ||||||
| NA | 9 (0.7) | 9 (0.9) | 0 | 0 | 0 | 0 |
| R | 140 (11.2) | 0 | 140 (46.4) | 73 (100) | 88 (56.8) | 140 (46.4) |
| S |
1,105 (88.1) |
943 (99.1) |
162 (53.6) |
0 |
67 (43.2) |
162 (53.6) |
| THA | ||||||
| R | 232 (18.5) | 172 (18.1) | 60 (19.9) | 8 (11.0) | 30 (19.4) | 22 (29.7) |
| S |
1,022 (81.5) |
780 (81.9) |
242 (80.1) |
65 (89.0) |
125 (80.6) |
52 (70.3) |
| PAS | ||||||
| R | 120 (9.6) | 48 (5.0) | 72 (23.8) | 13 (17.8) | 28 (18.1) | 31 (41.9) |
| S | 1,134 (90.4) | 904 (95.0) | 230 (76.2) | 60 (82.2) | 127 (81.9) | 43 (58.1) |
*AMK, amikacin; BDQ, bedaquiline; CAP, capreomycin; DST, drug-susceptibility testing; EMB, ethambutol; FQ, fluoroquinolone; INH, isoniazid; KAN, kanamycin; NA, not available; PAS, para-aminosalicylic acid; R, resistant; S, susceptible; SLI, second-line injectable drug; THA, ethionamide; XDR, extensively drug-resistant. †Comprises FQ-R only, SLI-R only, and XDR cases combined.